HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Bunn, P. A. Articles by Heasley, L. Search for Related Content PubMed PubMed Citation Articles by Bunn, P. A., Jr. Articles by Heasley, L.

New Therapeutic Strategies for Lung Cancer^*

Biology and Molecular Biology Come of Age

^* From the Lung Cancer Program, University of Colorado Cancer Center, Denver, CO.

Correspondence to: Paul A. Bunn, Jr., MD, University of Colorado Cancer Center, Box B-188, 4200 East 9th Ave, Denver, CO 80262; e-mail: paul.bunn{at}uchsc.edu

The current understanding of the biology and molecular biology of lung cancer pathogenesis and progression is reviewed. Awareness of the influence of growth factors, oncogenes, and tumor suppressor genes as well as signal transduction and angiogenesis pathways on the natural history of cancer cells has led to attempts to develop new therapeutic strategies directed at interrupting tumor cell growth. Treatments utilizing monoclonal antibodies, matrix metalloproteinase inhibitors, and gene transfer and alteration are currently being investigated. The rationale and effectiveness of these treatments in early trials are explored, and recommendations for future directions in cell biology research are presented. Interest in the biology and molecular biology of tumor cells has led to some important findings that may provide opportunities for new treatments. Several of these new directions for anticancer therapy are already being examined in phase I clinical trials.

Key Words: angiogenesis • apoptosis • growth factor • lung cancer • oncogene • receptors • suppressor gene

This article has been cited by other articles:

				A. J. Bauer, A. Patel, R. Terrell, K. Doniparthi, M. Saji, M. Ringel, R. M. Tuttle, and G. L. Francis Systemic Administration of Vascular Endothelial Growth Factor Monoclonal Antibody Reduces the Growth of Papillary Thyroid Carcinoma in a Nude Mouse Model Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 192 - 199. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				P. Song, H. S. Sekhon, Y. Jia, J. A. Keller, J. K. Blusztajn, G. P. Mark, and E. R. Spindel Acetylcholine Is Synthesized by and Acts as an Autocrine Growth Factor for Small Cell Lung Carcinoma Cancer Res., January 1, 2003; 63(1): 214 - 221. [Abstract] [Full Text] [PDF]

				K. H. Dragnev, D. Stover, and E. Dmitrovsky Lung Cancer Prevention: The Guidelines Chest, January 1, 2003; 123(1_suppl): 60S - 71S. [Abstract] [Full Text] [PDF]

				M. Paci, G. Sgarbi, G. Ferrari, S. De Franco, and V. Annessi Controversies Over UICC-TNM Classification of Non-small Cell Lung Cancer : Model for a Diagnostic Path Chest, August 1, 2002; 122(2): 754 - 754. [Full Text] [PDF]

				C. Yan, Y. Liang, K. D. Nylander, J. Wong, R. M. Rudavsky, H. U. Saragovi, and N. F. Schor p75-Nerve Growth Factor as an Antiapoptotic Complex: Independence versus Cooperativity in Protection from Enediyne Chemotherapeutic Agents Mol. Pharmacol., April 1, 2002; 61(4): 710 - 719. [Abstract] [Full Text] [PDF]